Category Archives: Business and Investments

Latest From Business and Investments

Will We Ever Have Genetically Modified Meat?

LBS-graphic-200x100 copy

Currently, there are no genetically engineered animals sold for human consumption on the market, reports Popular Science. As you might have guessed, the lack of genetically modified meat on the market isn’t because of a lack of technology or safety; it’s because of the politics. GM foods are deeply unpopular as of now, and GM food animals are especially so. After reading an article concerning GM animals from The Scientist showing how effective they can be, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Bioeconomics: Everybody’s Doing It

medical_research

It is everywhere. In March, the US State Department held a one-day conference titled “Showcasing the Bioeconomy: The Future is Now”. That same month, the UK House of Lords published a report on the same topic. “Waste could be turned into wealth,” they said. In the past couple of weeks, Finland’s first national bioeconomy strategy was unveiled, while the Borneo Post reported that “The vast potentiality of bioeconomy has been regarded as one of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Wanted: Tax Policies to Support Innovation

Research

Innovative small businesses work to advance research, development, and manufacturing of technologies to help solve economic, environmental, and societal challenges. The Coalition of Small Business Innovators is a national, non-partisan coalition of organizations dedicated to stimulating sustained, private investment in small companies focusing on the development of transformative, life-changing new technologies. Small business innovators are working every day to solve the greatest challenges facing our society – whether it’s finding a cure for cancer, developing Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Therapeutic Licensing and M&A Deals

lab_tech

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

New Type of Prospective Survey Initiative

scientist-eyedropper

Our industry is on the cutting-edge of science aimed at developing new therapies for devastating and life-threatening diseases. To help advance innovation and promote the development of the next generation of treatments and cures, we must acknowledge that the scientific method does not operate in a vacuum. Robust, interactive FDA-Sponsor communication is a key element of modern drug development. However, in order to improve the drug development enterprise and the FDA review process further, the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,